Skip to main content

Are you Dr. Gupta?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 36 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    400 E 34th St
    New York, NY 10016
    Phone+1 212-263-6952
    Fax+1 212-263-7146

Summary

  • Dr. Shalabh Gupta, MD is a physiatrist in New York, New York. He is currently licensed to practice medicine in New York and California.

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Physical Medicine and Rehabilitation, 2001 - 2004
  • Jawaharlal Institute of Postgraduate Medical Education and Research
    Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 1996

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2008 - 2026
  • NY State Medical License
    NY State Medical License 2004 - 2012

Publications & Presentations

PubMed

Press Mentions

  • Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
    Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of RenazorbDecember 28th, 2022
  • Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
    Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United KingdomDecember 22nd, 2022
  • Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (Lanthanum Dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
    Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (Lanthanum Dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on DialysisNovember 10th, 2022
  • Join now to see all